Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001]. Gastroenterol Hepatol 2002;25:162-9. [PMID: 11864540 DOI: 10.1016/s0210-5705(02)79012-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]

For:	Domènech E, Esteve-Comas M, Gomollón F, Hinojosa J, Obrador A, Panés J, Gassull MA. [Recommendations for the use of infliximab (Remicade) in Crohn's disease. GETECCU 2001]. Gastroenterol Hepatol 2002;25:162-9. [PMID: 11864540 DOI: 10.1016/s0210-5705(02)79012-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]

Number

Cited by Other Article(s)

Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F. [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. GASTROENTEROLOGIA Y HEPATOLOGIA 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/15/2013] [Accepted: 01/21/2013] [Indexed: 12/13/2022]

Carrasco Cubero C, Ruiz Tudela MM, Salaberri Maestrojuan JJ, Pérez Venegas JJ. Pioderma gangrenoso asociado a enfermedad inflamatoria intestinal. Descripción de 2 casos con buena respuesta a infliximab. ACTA ACUST UNITED AC 2012;8:90-2. [DOI: 10.1016/j.reuma.2011.07.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2011] [Revised: 06/03/2011] [Accepted: 07/27/2011] [Indexed: 10/15/2022]

Gisbert JP. [Ten major publications in 2010 with implications for clinical practice in gastroenterology]. GASTROENTEROLOGIA Y HEPATOLOGIA 2011;34:289-304. [PMID: 21474205 DOI: 10.1016/j.gastrohep.2011.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Accepted: 02/28/2011] [Indexed: 05/30/2023]

González-Lama Y, López-San Román A, Marín-Jiménez I, Casis B, Vera I, Bermejo F, Lázaro Pérez-Calle J, Taxonera C, Martínez-Silva F, Menchén L, Martínez-Montiel P, Calvo M, Antonio Carneros J, López P, Luis Mendoza J, María Milicua J, Huerta A, Sánchez F, Abreu L, López-Palacios N, Maté J, Gisberta JP. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. GASTROENTEROLOGIA Y HEPATOLOGIA 2008;31:421-6. [DOI: 10.1157/13125587] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

Gomollón F. Seguridad de los tratamientos en la enfermedad inflamatoria intestinal. GASTROENTEROLOGIA Y HEPATOLOGIA 2006. [DOI: 10.1157/13098294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]

López-San Román A, Obrador A, Fortún J, Muñoz P, Gassull MA. Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab. Actualización 2006. GASTROENTEROLOGIA Y HEPATOLOGIA 2006;29:81-4. [PMID: 16448610 DOI: 10.1157/13083915] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]

Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull MA. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. GASTROENTEROLOGIA Y HEPATOLOGIA 2005;28:126-34. [PMID: 15771858 DOI: 10.1157/13072012] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]

Domènech Morral E. [Indications for infliximab. How long should treatment last? Risk/benefit evaluation]. GASTROENTEROLOGIA Y HEPATOLOGIA 2004;27:172-6. [PMID: 14998471 DOI: 10.1016/s0210-5705(03)79119-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]

Maroto Arce N, Ponce M. [Tuberculosis and the digestive tract]. GASTROENTEROLOGIA Y HEPATOLOGIA 2003. [PMID: 12525327 DOI: 10.1016/s0210-5705(03)70339-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]

Castro Fernández M, García Díaz E, Romero M, Galán Jurado V, Rodríguez Alonso C. [Treatment of steroid-refractory ulcerative colitis with infliximab]. GASTROENTEROLOGIA Y HEPATOLOGIA 2003;26:54-5. [PMID: 12525332 DOI: 10.1016/s0210-5705(03)70344-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]